Last year, Congress passed the Mainstreaming Addiction Treatment (MAT) Act, seeking to expand access to buprenorphine, a proven treatment for opioid use disorder. However, a recent proposal by the Drug Enforcement Administration threatens to undermine Congress' intention. Now, some members of Congress appear ready to push back.
“Last month, California lawmakers passed a bill that would decriminalize the personal possession of small amounts of a few plant-based psychedelics. This raised hopes that this could be the first of many reforms to unlock the therapeutic potential of psychedelics. Unfortunately, Governor Newsom vetoed the bill, citing reasons that can only be characterized as specious.”
“It never made sense for the DEA to list marijuana as a Schedule I drug. Making it a Schedule III controlled substance will make researching the drug’s medicinal uses easier. But it still makes federal criminals of the millions of adults who have been using marijuana recreationally for millennia and makes as much sense as it does to require people to get a prescription to ingest beer, wine, or whiskey.”
Recently, Newsday's David Olson wrote about opioids in an honest way not often seen in mainstream media. He emphasized the harm caused by the “overcorrection of the pendulum” – the shortage of medically legitimate opioids caused by ill-advised restrictions on prescribing. He gives personal accounts of practitioners, pharmacists, and patients struggling to navigate the unforgiving terrain of new laws and policies. Thumbs up to Mr. Olson for this important article.
Clinical researchers have recognized the therapeutic potential of psychedelics for decades. In recent years, veterans groups and some lawmakers have also begun to appreciate this. But none of that matters if law enforcement disagrees.
For the past five years, the DEA has classified fentanyl-related substances as Schedule 1 drugs, hoping it will reduce fentanyl-related overdose deaths . Deaths have nearly doubled since then. But, inexplicably, some in Congress think that placing fentanyl-related substances permanently on Schedule 1 will bring the overdose rate down.“
It should come as no surprise to anyone trying to get or fill a prescription for a controlled substance that our drug laws are nuts. But you probably don't fully appreciate how nutty they really are. This article just scratches the surface of the nut. But that's still plenty.
The shortage of Adderall, an important medication used to treat ADHD – attention deficit/hyperactivity disorder – is a story of supply, demand, the invisible hand of market forces. It’s also about a bureaucracy focused on regulation rather than outcome. It has all the hallmarks of the opioid crisis. We have learned nothing.
In response to Tranq – a horrifying "new" drug sweeping the nation – Kolodny, America's "drug expert," proposes a solution. And gets it all wrong.
A unanimous Supreme Court decision is a good first step for getting law enforcement out of prescription decisions. Drs. Jeffrey Singer and Josh Bloom in Reason Magazine.
The DEA lifted its 2007 ban on methadone clinics sending out mobile units to reach people in communities underserved by the clinics. But patients are required to take the methadone in the presence of clinic staff. A better solution is to let doctors prescribe take-home methadone, like they do in Canada, UK, Australia--and they were permitted to do as an emergency measure during the pandemic.
In today's "just when you think it can't get any worse" feature, DEA agents are now seizing counterfeit Adderall pills that contain pure methamphetamine. Although Mexican drug cartels are blamed for making these pills to get young people addicted to meth, the ultimate blame falls on DEA policies. What a mess.